Antibacterial Therapy Options for Infections Caused by Carbapenem-Resistant Acinetobacter baumannii

Abstract

The review presents current treatment regimens for infections associated with carbapenem-resistant Acinetobacter baumannii, which are leading nosocomial pathogens exhibiting multidrug resistance to available antibacterial drugs. To date, widely used beta-lactam antibiotics, including carbapenems, have lost their effectiveness in combating acinetobacter infections, while new antibiotics remain poorly available to patients. Therefore, the only measure to combat the antibiotic resistance of carbapenem-resistant A. baumannii is to evaluate the efficiency of combination therapy in vitro and in vivo, which is of particular interest to Russian and foreign researchers.